Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study
Wei-Hsiang Tseng, Cheng-Hsien Lin, Yu-Chen Su, Ling-Chiao Teng, Chieh‐Lin Jerry Teng · 2026
Read Cytomegalovirus prophylaxis using low-dose and ultra-low-dose valganciclovir for patients who have undergone allogeneic hematopoietic stem cell transplantation: A retrospective study by Wei-Hsiang Tseng, Cheng-Hsien Lin, Yu-Chen Su, Ling-Chiao Teng, Chieh‐Lin Jerry Teng (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13263491.txt.
Description
Wei-Hsiang Tseng and co-authors report a 2026 journal article on preventing cytomegalovirus infection after stem cell transplantation. The virus often reactivates when immunity is suppressed. The preventive drug valganciclovir can itself lower blood counts, so the team compared a low daily dose with an ultra-low dose given every other day.
Among 66 patients, early virus reactivation was somewhat more common on the ultra-low dose, about twenty percent against about fourteen, but the gap was not statistically significant. Late reactivation was rare in both groups. The important difference was tolerance: nearly half of the low-dose group had to stop treatment over low blood counts, against about seventeen percent on ultra-low dosing. Survival was similar.
Catalog record
| CREATOR | Wei-Hsiang Tseng, Cheng-Hsien Lin, Yu-Chen Su, Ling-Chiao Teng, Chieh‐Lin Jerry Teng |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30834 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |